Ocrevus (ocrelizumab) was approved as a new treatment for Multiple Sclerosis in March of 2017. It is an infusion that patients have every six months, aside from the first two doses (which are one-half, two weeks apart). As one of the hot new medications on the market, a lot of patients are showing interest in switching to this treatment. Before you make the switch, take a minute to learn what you can expect at your first infusion.
Prior to scheduling your infusion, make sure you have completed all required bloodwork and that you have an up-to-date MRI on file. Ocrevus also has a co-pay program that you can sign up for but you’ll need to do that and be accepted before your first infusion. While you’re waiting on approval (usually handled by your doctor), ask your doctor any questions you may have about Ocrevus, potential side effects and what the mechanism of action is.
Click here to read the rest of this post.